TSE:2160Biotechs
Does First Phase 2/3 Pirfenidone Trial in Oncology Supportive Care Change The Bull Case For GNI Group (TSE:2160)?
GNI Group Ltd. announced that its consolidated subsidiary, Gyre Pharmaceuticals, has enrolled the first patient in a Phase 2/3 trial of its self-developed pirfenidone capsules (Etuary®) for radiation-induced lung injury with or without immune checkpoint inhibitor-related pneumonitis, following Chinese regulatory approval in March 2025.
This step advances pirfenidone into oncology supportive care, targeting a serious complication of thoracic cancer treatment where current therapeutic options...